Localized primary malignant lymphoma of bone

Praveen Dubey, Chul S. Ha, Pelayo C. Besa, Lillian Fuller, Fernando Cabanillas, John Murray, Mark A. Hess, James D Cox

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Purpose: A single institution's experience with the treatment of localized primary malignant lymphoma of bone as analyzed to identify major prognostic factors, toxicity, and optimal treatment for this rare malignancy. Methods and Materials: A retrospective analysis of 45 previously untreated patients with Ann Arbor stage IE and IIE PLB from 1967 to 1992 was undertaken. All histopathologic material was reviewed. Irradiated patients received at least 40 Gy. Systemic chemotherapy was generally doxorubicin based. Overall survival (OS), progression free survival (PFS), and disease- specific survival (DSS) were calculated actuarially. Results: Histologically, there were 41 diffuse large cell, 2 diffuse mixed cell, 1 lymphocytic, and 1 lymphoblastic lymphomas. International Index scores were assessed on 43 patients. Thirty-six patients were treated with chemotherapy and radiation (CMT), five patients were treated with radiation only, and four patients were treated with chemotherapy only. Univariate analysis revealed significantly improved 5-year OS for those patients who had International Index scores of 0 vs. scores of 1 or 2 (85 vs. 53%, respectively, p = 0.004). Analysis failed to demonstrate a difference in OS, PFS, or DSS when comparing radiotherapy alone versus CMT, stage IE vs. stage IIE, or axial skeleton involvement vs. extremities. Conclusion: The outcome of patients with PLB is relatively favorable in the era of CMT. Doses of radiation in the range of 46 Gy provide optimal local control with an acceptable rate of complications. The International Index is a valid prognostic tool for PLB.

Original languageEnglish (US)
Pages (from-to)1087-1093
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume37
Issue number5
DOIs
StatePublished - Mar 15 1997

Fingerprint

bones
Lymphoma
chemotherapy
Bone and Bones
Radiation
Drug Therapy
Survival
radiation
progressions
Disease-Free Survival
cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
musculoskeletal system
Skeleton
toxicity
Doxorubicin
radiation therapy
Radiotherapy
Extremities
dosage

Keywords

  • Bone
  • International Index
  • Lymphoma
  • Radiotherapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Dubey, P., Ha, C. S., Besa, P. C., Fuller, L., Cabanillas, F., Murray, J., ... Cox, J. D. (1997). Localized primary malignant lymphoma of bone. International Journal of Radiation Oncology Biology Physics, 37(5), 1087-1093. https://doi.org/10.1016/S0360-3016(97)00106-5

Localized primary malignant lymphoma of bone. / Dubey, Praveen; Ha, Chul S.; Besa, Pelayo C.; Fuller, Lillian; Cabanillas, Fernando; Murray, John; Hess, Mark A.; Cox, James D.

In: International Journal of Radiation Oncology Biology Physics, Vol. 37, No. 5, 15.03.1997, p. 1087-1093.

Research output: Contribution to journalArticle

Dubey, P, Ha, CS, Besa, PC, Fuller, L, Cabanillas, F, Murray, J, Hess, MA & Cox, JD 1997, 'Localized primary malignant lymphoma of bone', International Journal of Radiation Oncology Biology Physics, vol. 37, no. 5, pp. 1087-1093. https://doi.org/10.1016/S0360-3016(97)00106-5
Dubey, Praveen ; Ha, Chul S. ; Besa, Pelayo C. ; Fuller, Lillian ; Cabanillas, Fernando ; Murray, John ; Hess, Mark A. ; Cox, James D. / Localized primary malignant lymphoma of bone. In: International Journal of Radiation Oncology Biology Physics. 1997 ; Vol. 37, No. 5. pp. 1087-1093.
@article{836358a27924402bb6faeee378d1e37f,
title = "Localized primary malignant lymphoma of bone",
abstract = "Purpose: A single institution's experience with the treatment of localized primary malignant lymphoma of bone as analyzed to identify major prognostic factors, toxicity, and optimal treatment for this rare malignancy. Methods and Materials: A retrospective analysis of 45 previously untreated patients with Ann Arbor stage IE and IIE PLB from 1967 to 1992 was undertaken. All histopathologic material was reviewed. Irradiated patients received at least 40 Gy. Systemic chemotherapy was generally doxorubicin based. Overall survival (OS), progression free survival (PFS), and disease- specific survival (DSS) were calculated actuarially. Results: Histologically, there were 41 diffuse large cell, 2 diffuse mixed cell, 1 lymphocytic, and 1 lymphoblastic lymphomas. International Index scores were assessed on 43 patients. Thirty-six patients were treated with chemotherapy and radiation (CMT), five patients were treated with radiation only, and four patients were treated with chemotherapy only. Univariate analysis revealed significantly improved 5-year OS for those patients who had International Index scores of 0 vs. scores of 1 or 2 (85 vs. 53{\%}, respectively, p = 0.004). Analysis failed to demonstrate a difference in OS, PFS, or DSS when comparing radiotherapy alone versus CMT, stage IE vs. stage IIE, or axial skeleton involvement vs. extremities. Conclusion: The outcome of patients with PLB is relatively favorable in the era of CMT. Doses of radiation in the range of 46 Gy provide optimal local control with an acceptable rate of complications. The International Index is a valid prognostic tool for PLB.",
keywords = "Bone, International Index, Lymphoma, Radiotherapy",
author = "Praveen Dubey and Ha, {Chul S.} and Besa, {Pelayo C.} and Lillian Fuller and Fernando Cabanillas and John Murray and Hess, {Mark A.} and Cox, {James D}",
year = "1997",
month = "3",
day = "15",
doi = "10.1016/S0360-3016(97)00106-5",
language = "English (US)",
volume = "37",
pages = "1087--1093",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Localized primary malignant lymphoma of bone

AU - Dubey, Praveen

AU - Ha, Chul S.

AU - Besa, Pelayo C.

AU - Fuller, Lillian

AU - Cabanillas, Fernando

AU - Murray, John

AU - Hess, Mark A.

AU - Cox, James D

PY - 1997/3/15

Y1 - 1997/3/15

N2 - Purpose: A single institution's experience with the treatment of localized primary malignant lymphoma of bone as analyzed to identify major prognostic factors, toxicity, and optimal treatment for this rare malignancy. Methods and Materials: A retrospective analysis of 45 previously untreated patients with Ann Arbor stage IE and IIE PLB from 1967 to 1992 was undertaken. All histopathologic material was reviewed. Irradiated patients received at least 40 Gy. Systemic chemotherapy was generally doxorubicin based. Overall survival (OS), progression free survival (PFS), and disease- specific survival (DSS) were calculated actuarially. Results: Histologically, there were 41 diffuse large cell, 2 diffuse mixed cell, 1 lymphocytic, and 1 lymphoblastic lymphomas. International Index scores were assessed on 43 patients. Thirty-six patients were treated with chemotherapy and radiation (CMT), five patients were treated with radiation only, and four patients were treated with chemotherapy only. Univariate analysis revealed significantly improved 5-year OS for those patients who had International Index scores of 0 vs. scores of 1 or 2 (85 vs. 53%, respectively, p = 0.004). Analysis failed to demonstrate a difference in OS, PFS, or DSS when comparing radiotherapy alone versus CMT, stage IE vs. stage IIE, or axial skeleton involvement vs. extremities. Conclusion: The outcome of patients with PLB is relatively favorable in the era of CMT. Doses of radiation in the range of 46 Gy provide optimal local control with an acceptable rate of complications. The International Index is a valid prognostic tool for PLB.

AB - Purpose: A single institution's experience with the treatment of localized primary malignant lymphoma of bone as analyzed to identify major prognostic factors, toxicity, and optimal treatment for this rare malignancy. Methods and Materials: A retrospective analysis of 45 previously untreated patients with Ann Arbor stage IE and IIE PLB from 1967 to 1992 was undertaken. All histopathologic material was reviewed. Irradiated patients received at least 40 Gy. Systemic chemotherapy was generally doxorubicin based. Overall survival (OS), progression free survival (PFS), and disease- specific survival (DSS) were calculated actuarially. Results: Histologically, there were 41 diffuse large cell, 2 diffuse mixed cell, 1 lymphocytic, and 1 lymphoblastic lymphomas. International Index scores were assessed on 43 patients. Thirty-six patients were treated with chemotherapy and radiation (CMT), five patients were treated with radiation only, and four patients were treated with chemotherapy only. Univariate analysis revealed significantly improved 5-year OS for those patients who had International Index scores of 0 vs. scores of 1 or 2 (85 vs. 53%, respectively, p = 0.004). Analysis failed to demonstrate a difference in OS, PFS, or DSS when comparing radiotherapy alone versus CMT, stage IE vs. stage IIE, or axial skeleton involvement vs. extremities. Conclusion: The outcome of patients with PLB is relatively favorable in the era of CMT. Doses of radiation in the range of 46 Gy provide optimal local control with an acceptable rate of complications. The International Index is a valid prognostic tool for PLB.

KW - Bone

KW - International Index

KW - Lymphoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0030973311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030973311&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(97)00106-5

DO - 10.1016/S0360-3016(97)00106-5

M3 - Article

C2 - 9169817

AN - SCOPUS:0030973311

VL - 37

SP - 1087

EP - 1093

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -